At a glance
ClinicalIndex Comparison RecordPhase 2Active· 26 target
Drug / intervention
Anlotinib + Cadonilimab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Trial of Anlotinib Combined With Cadonilimab and PULSAR in Previously Treated Advanced Unresectable or Metastatic Biliary Tract Cancer
In Brief
A Phase 2 clinical trial evaluating Anlotinib + Cadonilimab and PULSAR for Previously Treated, Advanced and Biliary Tract Cancers. Active but no longer recruiting, targeting 26 participants across 1 site.
Detailed Summary
This study aims to evaluate the safety and preliminary efficacy of anlotinib combined with cadonilimab and PULSAR in previously treated advanced unresectable or netastatic biliary tract cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
CollaboratorsChia Tai Tianqing Pharmaceutical Group Co., Ltd., Akeso
Timeline
Phase 2Active
20272028
Enrollment StartJun 2026
First PostedJun 2026
TodayJul 2026
Primary CompletionJun 2027
Study CompletionJun 2028
First PostedJun 9, 2026
Enrollment StartJun 3, 2026
Primary CompletionJun 30, 2027
Study CompletionJun 30, 2028
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 23 days agoPrimary completion in 12 months
Arms & Interventions
Anlotinib + Cadonilimab + PULSARexperimental
Drug: Anlotinib + CadonilimabRadiation: PULSAR
Interventions
Anlotinib + Cadonilimabdrug
Anlotinib Combined with Cadonilimab
PULSARradiation
Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy